| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000023319 |
| Receipt No. | R000026868 |
| Official scientific title of the study | Non-randomized, single-center study for efficacy and safety of telemonitoring in the continuous positive airway pressure treatment for patient with newly diagnosed sleep apnea syndrome |
| Date of disclosure of the study information | 2016/07/25 |
| Last modified on | 2016/07/25 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Non-randomized, single-center study for efficacy and safety of telemonitoring in the continuous positive airway pressure treatment for patient with newly diagnosed sleep apnea syndrome | |
| Title of the study (Brief title) | Telemonitoring study of CPAP for SAS | |
| Region |
|
|
| Condition | ||
| Condition | The patients who are newly diagnosed as sleep apnea syndrome and start continuous positive airway pressure treatment | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We apply clouded CPAP monitoring system for newly diagnosed sleep apnea syndrome and follow 3 months. The primary endpoint is average time of CPAP use on days used. Historical control is the previous data of the patients who were monitored by SD card. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | Average time of CPAP use on days used 3 months after CPAP introduction. |
| Key secondary outcomes | 1. Drop-out rate
2. The percentage of CPAP usage less than 4 hours 3. Average CPAP use on whole days 4. Residual AHI 5. Mask leak 6. Japanese Excessive sleepiness score 7. SF-36 8. Reason that stopped therapy 9.Travelling time to the hospital for patient 10. Time to follow up and care patient for doctors and co-medicals. 11. Time for care of patient for home care provider |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | ICT Group 60 samples.
For ICT group, use of CPAP is monitored by cloud server on the 3rd,7th and 14th day after the start of therapy as well as after one and two months. Communication by telephone and mail, total work hours of healthcare professionals and employees of CPAP rental company are measured and recorded. |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Outpatient only
2. Diagnosed as obstructive sleep apnea syndrome (OSAS) and has apnea-hypopnea Index (AHI) higher than 20 by polysomnography (PSG) 3. Direct contact is possible by telephone or e-mail 4. Patient who agreed to participate to this clinical study by written informed concent by his/her own free will after being well informed and understanding about this study. |
|||
| Key exclusion criteria | Patients who meet one of the following criteria are excluded.
1. Patients with predominant central sleep apnea (CSA) 2. Patients with severe heart failure 3. Patient with severe respiratory failure 4. Patient with dementia 5. Patients with severe sleep disorder except SAS 6. Patients who some significant disease which influences CPAP therapy 7. Patients with claustrophobia 8. Patients who has past history of CPAP therapy. 9. Patients who want to be treated with oral appliance 10. Patients with significant nasal obstruction. 11. Occupational bus, truck, and taxi drivers who are screened by regular check-up, diagnosed as SAS, and introduced CPAP treatment. 12. Patient who sleeps without intending 13. Patients who cannot be contacted by telephone or e-mail regularly 14. Patients who participated in the other clinical study in last four months 15. Patients who are regularly visit our hospital with interval shorter than 3 months 16. Patients who are assessed as inadequate as the object of this clinical study by principal investigator |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroyuki Yoshimine |
| Organization | Inoue Hospital |
| Division name | Internal Medicine |
| Address | 6-12 Takara-machi, Nagasaki-city |
| TEL | 095-844-1281 |
| yoshy@shunkaikai.jp | |
| Public contact | |
| Name of contact person | Hiroyuki Yoshimine |
| Organization | Inoue Hospital |
| Division name | Internal Medicine |
| Address | 6-12 Takara-machi, Nagasaki-city |
| TEL | 095-844-1281 |
| Homepage URL | |
| yoshy@shunkaikai.jp | |
| Sponsor | |
| Institute | Inoue Hospital |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | ResMed Japan KK |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Nagasaki University
Yamax |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026868 |